Skip to main content

Ninlaro FDA Approval History

FDA Approved: Yes (First approved November 20, 2015)
Brand name: Ninlaro
Generic name: ixazomib
Dosage form: Capsules
Company: Takeda Pharmaceutical Company Limited
Treatment for: Multiple Myeloma

Ninlaro (ixazomib) is an oral proteasome inhibitor indicated for use in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.

Development timeline for Ninlaro

DateArticle
Nov 20, 2015Approval FDA Approves Ninlaro (ixazomib) for Multiple Myeloma
Sep  9, 2015U.S. FDA Grants Priority Review to Takeda's Ixazomib for Patients with Relapsed/Refractory Multiple Myeloma
Jul 15, 2015Takeda Submits NDA for Ixazomib for Patients with Relapsed/Refractory Multiple Myeloma

See also

Ninlaro (ixazomib) Consumer information

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer